healthprotocol.wiki

boulware_2023_rct_oral-lipid-nanocrystal-amphotericin-b-for-cryptococcal-meningitis

6 findings

Protocol
medication-oral-lipid-nanocrystal-amphotericin-b-high-dose-flucytosine-two-weeks-then-lower-dose-six-weeks-generic
Outcome
cerebrospinal-fluid-csf-early-fungicidal-activity-log10-cfu-per-ml-per-day-measured
n
80
effect
0
attribution
85
Protocol
medication-oral-lipid-nanocrystal-amphotericin-b-high-dose-flucytosine-two-weeks-then-lower-dose-six-weeks-generic
Outcome
cerebrospinal-fluid-csf-sterility-at-2-weeks-binary-measured
n
80
effect
0
attribution
85
Protocol
medication-oral-lipid-nanocrystal-amphotericin-b-high-dose-flucytosine-two-weeks-then-lower-dose-six-weeks-generic
Outcome
safety-treatment-related-anemia-grade-3-4-incidence-cohort-measured
n
80
effect
23
attribution
85
Protocol
medication-oral-lipid-nanocrystal-amphotericin-b-high-dose-flucytosine-two-weeks-then-lower-dose-six-weeks-generic
Outcome
safety-treatment-related-grade-3-4-laboratory-adverse-events-incidence-cohort-measured
n
80
effect
20
attribution
85
Protocol
medication-oral-lipid-nanocrystal-amphotericin-b-high-dose-flucytosine-two-weeks-then-lower-dose-six-weeks-generic
Outcome
safety-treatment-related-hypokalemia-grade-3-4-incidence-cohort-measured
n
80
effect
12
attribution
85
Protocol
medication-oral-lipid-nanocrystal-amphotericin-b-high-dose-flucytosine-two-weeks-then-lower-dose-six-weeks-generic
Outcome
survival-overall-at-18-weeks-proportion-cohort-measured
n
80
effect
0
attribution
85